The Delhi High Court on Thursday (1 December) quashed the centre's notification to ban 344 fixed dose combination (FDC) medicines. The brands included D'Cold Total, Corex cough syrup and Vicks Action 500, among others.
Justice R S Endlaw, allowing the 454 pleas filed by the pharma companies, quashed the centre's notification issued on 10 March. Companies like Pfizer, Glenmark, Procter and Gamble, Reckitt Benckiser, Cipla and others had moved the court against the government’s decision. The court had granted stay on the notification.
The government had told the court that FDC medicines sold by pharma majors "endanger patient safety". It had banned the drugs on the ground that they involve risk to humans and, therefore, needed to be withdrawn immediately and contended that safer alternatives were available.
The pharma companies had argued that the ban order was passed without considering clinical data and had termed the government's claim as absurd.
With inputs from IANS
An appeal from Swarajya
At Swarajya, we rely on our readers' support through subscriptions to sustain our media platform. Unlike larger conglomerates, we are unable to relentlessly chase advertising money — our model is largely built on your patronage.
Your support has never been more crucial. We work tirelessly to deliver 10-15 high-quality articles daily, ensuring you receive insightful content from 7 AM to 10 PM.
If you believe India's story has to be articulated in a way it has never been done before without shrugging it off, become a patron (or) subscribe now for ₹̶2̶4̶0̶0̶ ₹1999 and get 12 print issues, unlimited digital access for 1 year, a special India that is Bharat T-shirt (Offer ends soon).
We are counting on you!